NEW YORK (GenomeWeb News) – NeoProteomics announced on Tuesday it has been awarded a two-year, $300,000 grant from the National Institutes of Health to develop software for commercial applications.
The Small Business Innovation Research grant will be used by the Cleveland-based protein biomarker development and software firm to develop applications for four software programs that it has licensed from Case Western Reserve University, from which NeoProteomics was spun out in 2006.
The software programs are to improve understanding of biology at a molecular level which can lead to better treatments for cancer and other diseases, the company said, adding that the SBIR grant will cover a "significant" portion of costs associated with developing the software for commercial use.
NeoProteomics plans to use the license to develop a set of products for the diagnosis of disease, prediction of disease progression, and prediction of patient response to specific treatments, Mark Chance, co-founder and chief scientific officer of the company, said in a statement.
Rod Nibbe, director of product development and senior scientist at NeoProteomics, will serve as principal investigator on the grant.
"Understanding the molecular mechanisms of complex biology inherent to many cancers and other diseases, such as Alzheimer's, and the related efforts to discover new drug targets are time consuming and expensive," Nibbe said in a statement. "Our software is intended to help academic and industrial researchers unravel the biological complexity, and by doing so lower the cost and shorten the time to development of new therapeutic agents."